ArticleCNS drugs2018
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential.
Article in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01721161 (A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Magnetoencephalography biomarkers for assessing myelin content and neuronal function in acute optic neuritis.Brain communications · 2026Article
- Article
- Review
- Toward isolating perceptual and physiological contributors to heat sensitivity in multiple sclerosis: insights from a new experimental model.European journal of applied physiology · 2025Article
- The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with optic neuritis.Journal of neurology · 2025Article
- Assessing the visual afferent pathway with the multifocal visual evoked potentials in the radiologically isolated syndrome.Scientific reports · 2024Observational
- Visual outcome measures in clinical trials of remyelinating drugs.BMJ neurology open · 2024Review
- A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage.Brain : a journal of neurology · 2023Article
- Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration.International journal of molecular sciences · 2023Review
- Nogo receptor-Fc delivered by haematopoietic cells enhances neurorepair in a multiple sclerosis model.Brain communications · 2023Article
- Utility of the visual system to monitor neurodegeneration in multiple sclerosis.Frontiers in molecular neuroscience · 2023Review
- Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders.Neurology(R) neuroimmunology & neuroinflammation · 2022Review
- Analysis of Multifocal Visual Evoked Potentials Using Artificial Intelligence Algorithms.Translational vision science & technology · 2022Article
- Remyelination Trials: Are We Expecting the Unexpected?Neurology(R) neuroimmunology & neuroinflammation · 2021Review
- Review
- Role of Multifocal Visually Evoked Potential as a Biomarker of Demyelination, Spontaneous Remyelination, and Myelin Repair in Multiple Sclerosis.Frontiers in neuroscience · 2021Review
- Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis.PloS one · 2021Article
- Myelin Repair: From Animal Models to Humans.Frontiers in cellular neuroscience · 2021Review
- Retinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients.BMC neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. MF-VEP may offer advantages over FF-VEP as an endpoint in clinical trials of remyelinating therapies.
objectiveMF-VEP testing was used to study changes in visual pathways in 48% of RENEW [phase II, opicinumab (anti-LINGO-1; BIIB033) vs. placebo after first acute unilateral optic neuritis] participants.
methodsThis exploratory MF-VEP RENEW substudy compared mean outcomes at weeks 24 and 32 among participants in the intent-to-treat (ITT; n = 39; 72% female; mean age: 32.3 years) and per-protocol (PP; n = 31; 71% female; mean age: 32.2 years) populations in affected and fellow eye latency from fellow eye baseline latency and affected and fellow eye amplitude from their own baselines. Treatment differences were evaluated using analysis of covariance (week 24) and a mixed-effect model of repeated measures (week 32). Last observation carried forward was used to impute missing data at week 24.
resultsA trend for improvement in affected eye MF-VEP latency with opicinumab versus placebo was seen in the ITT and PP populations at weeks 24 and 32. Both treatment groups in the ITT population experienced partial recovery of amplitude in the affected eye at week 32. Notably, the mean change in fellow eye amplitude at weeks 24 and 32 was - 17.57 and - 31.41 nanovolts (nV) in placebo but only - 0.59 and 1.93 nV in the opicinumab group [differences at weeks 24 and 32: 16.98 nV (p = 0.050) and 33.33 nV (p < 0.01), respectively].
conclusionResults from this substudy showed advantages of MF-VEP over FF-VEP in multicenter studies of central nervous system reparative therapies and provide novel evidence that fellow eye visual pathway amplitude loss occurs after optic neuritis but can potentially be prevented by opicinumab treatment. REGISTRATION: ClinicalTrials.gov identifier NCT01721161.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.